含吲哚美辛无框架铜宫内节育器联合LNG-IUS治疗子宫腺肌病的临床研究
本研究前瞻性纳入91例子宫腺肌病患者,比较LNG-IUS单用与联合无框架铜IUD(含或不含吲哚美辛)的疗效与安全性。随访12个月发现,联合组无完全脱落或下移,而单用组完全脱落率为17.24%;含吲哚美辛联合组在缩小子宫体积、降低PBAC和VAS评分及不规则出血率方面表现更优。
要点
- 联合组无完全脱落或下移,单用LNG-IUS组完全脱落率为17.24%。
- 含吲哚美辛联合组从3个月起子宫体积显著小于其他两组(P<0.05)。
- 含吲哚美辛联合组不规则出血率3.13%,低于单用组的10.34%。
核心结论
- 在12个月随访中,联合组无完全脱落或严重下移,单用LNG-IUS组完全脱落率为17.24%。
- 三种方案均改善子宫体积、血红蛋白、月经失血和痛经,含吲哚美辛联合组在子宫体积、PBAC和VAS评分下降及不规则出血率最低方面最优。
研究设计与样本
- 前瞻性研究,纳入91例子宫腺肌病患者,按治疗偏好分为三组:A组LNG-IUS单用(n=29),B组LNG-IUS联合GyneFix®(n=30),C组LNG-IUS联合含吲哚美辛无框架铜IUD Jenefox(n=32)。
- 随访12个月,监测基线数据、不良事件(完全脱落、下移和取出)及疗效指标(子宫体积、血红蛋白、PBAC评分、VAS评分)。
主要发现
- A组完全脱落率为17.24%,B组和C组无完全脱落或下移发生。
- C组从3个月起子宫体积显著小于A组和B组(P<0.05)。
- B组和C组PBAC评分显著低于A组,C组改善更优(P<0.05)。
- C组在6个月内VAS评分低于A组和B组(P<0.05),B组在12个月时优于A组。
- C组不规则出血率3.13%,低于A组的10.34%,且无腹痛/背痛(P<0.05)。
关键数值与推荐
- A组完全脱落率17.24%,B组和C组均为0%。
- C组不规则出血率3.13%,A组10.34%(P<0.05)。
- C组子宫体积从3个月起显著小于A组和B组(P<0.05)。
临床怎么用
- 对于高脱落风险的子宫腺肌病患者,可考虑LNG-IUS联合无框架铜IUD的双装置方案。
- 含吲哚美辛的无框架铜IUD联合方案可能更有利于缩小子宫体积、减少出血和疼痛。
局限性
- 单中心队列研究,样本量较小(共91例)。
- 分组基于治疗偏好,非随机分配。
- 随访时间仅12个月。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
OBJECTIVE: To evaluate the safety and therapeutic efficacy of LNG-IUS alone versus LNG-IUS combined with frameless anchoring copper intrauterine device (IUD) (with or without indomethacin) in treating adenomyosis, and to explore the role of indomethacin in improving outcomes. STUDY DESIGN: A prospective study was conducted on 91 adenomyosis patients at Zhengzhou First People's Hospital (January 2022-January 2025), divided into three groups: Group A received LNG-IUS monotherapy alone (n = 29); Group B was treated with LNG-IUS combined with GyneFix® (GyneFix IN), a drug-free frameless copper IUD without indomethacin (n = 30); Group C received LNG-IUS paired with Jenefox (Jinizhimei), an indomethacin-loaded frameless copper IUD (n = 32).Baseline data, adverse events (complete expulsion, downward displacement and Removal), and efficacy indicators (uterine volume, hemoglobin [HGB], pictorial blood loss assessment chart [PBAC] score, visual analogue scale [VAS] score) were monitored during 12 months of follow-up. SETTING: Single tertiary hospital gynecology department affiliated to Xinxiang Medical College, Zhengzhou, China. PATIENTS: Women aged 30-52 years with ultrasonically confirmed symptomatic diffuse adenomyosis without fertility demands were enrolled. All subjects declined hysterectomy and long-term systemic hormonal medication, and agreed to complete all scheduled follow-up examinations. Patients with congenital uterine malformations, submucous fibroids, recent pelvic inflammatory disease, coagulation disorders, severe uncontrolled systemic diseases, or malignant gynecologic lesions were excluded. A total of 91 patients were allocated into three groups by treatment preference: Group A (LNG-IUS alone, n=29), Group B (LNG-IUS + GyneFix®, n=30), Group C (LNG-IUS + Jenefox, n=32). Baseline demographic and clinical parameters were balanced across the three groups (all P>0.05). INTERVENTIONS: Placement of standalone LNG-IUS, combined LNG-IUS with indomethacin-free frameless copper IUD, or combined LNG-IUS with indomethacin-containing frameless copper IUD under transabdominal ultrasound guidance. The LNG-IUS was ligated to the anchoring knot of frameless copper IUD to form a dual-device system, which was anchored into the uterine myometrium during insertion; diagnostic hysteroscopy was performed immediately after placement to inspect the uterine cavity in combined-device groups. MEASUREMENTS AND MAIN RESULTS: Baseline characteristics were comparable among groups. Group A had a 17.24% complete expulsion rate, while no complete expulsion/ downward displacement occurred in Groups B and C. Group C showed significantly smaller uterine volume than Groups A and B from 3 months onward (P<0.05). PBAC scores in Groups B and C were significantly lower than in Group A, with Group C exhibiting better improvement (P<0.05). Group C had lower VAS scores than A and B within 6 months (P<0.05), and Group B outperformed A at 12 months. Adverse events were mild and self-limiting; Group C had a lower irregular bleeding rate (3.13%) than Group A (10.34%) and no abdominal/back pain (P<0.05). CONCLUSION: Within the 12-month follow-up of this single-center cohort, no complete IUD expulsion or severe uterine downward displacement occurred in Groups B and C, whereas the LNG-IUS monotherapy group had a complete expulsion rate of 17.24%. All three regimens improved uterine volume, hemoglobin, menstrual blood loss and dysmenorrhea, and Group C achieved the most pronounced reductions in uterine volume, PBAC and VAS scores, with the lowest rate of irregular bleeding. The dual-device regimens therefore represent promising uterus-sparing conservative options for adenomyosis patients at high risk of IUD expulsion.
引用
- Li T, Wei J, Shi J, et al. Clinical study of a frameless indomethacin-containing copper intrauterine device combined with levonorgestrel-releasing intrauterine system in the treatment of adenomyosis. J Minim Invasive Gynecol. 2026. PMID: 42933564. doi:10.1016/j.jmig.2026.10.014
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。